Grant: Engage Grants Program
University of Alberta
$25,000.00
Advanced mass spectrometry applied to UV-treated biopharmaceutical fluids
FY 2016-17
Summary
Trojan Technologies is developing ultraviolet (UV) reactors to disinfect cell-culture media for use inbiopharmaceutical production. These media contain complex mixtures of amino acids, carbohydrates, vitamins,minerals, and, in some cases, serum. The industry has a significant problem with contamination by small,non-enveloped viruses that can evade the conventional filtration and chemical disinfection methods, and UVcan eliminate these infectious agents. The biopharmaceutical industry is adopting sterile, single-use disposabledevices for drug production in order to eliminate the need for on-site cleaning and sterilization, and to increaseproduct safety. Trojan has developed and is testing a prototype disposable UV system based on Teflon, one ofthe few polymers that is UV-transparent.The United States Food and Drug Administration (FDA) requires the evaluation of all wetted parts that maypotentially contaminate the drug supply process to quantify ""leachable and extractible"" compounds. Guidancefor setting limits for leachable and extractible compounds can be found in the United States PharmacopeialConvention (USP) documents (e.g., 661, 1151, 601 and 1664) and the International Conference onHarmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use ICHQ6A. Specific tests and levels are not prescribed, but are determined in consultation with the FDA on acase-by-case basis.The challenge in quantifying leachable compounds from the UV-Teflon devices is that the Teflon present inanalytical instruments such as LC-MS contributes background to the sample being analyzed. Dr Li's team at theUniversity of Alberta has the expertise and specialized equipment to develop methods for addressing thesechallenges. Trojan and Dr. Li's team will solve these issues, creating the potential fro the prototype to enter themarket of disinfecting biopharmaceutical fluids, estimated at tens of millions of dollars annually.
Program
Engage Grants Program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
504156-2016
Name nom
Li, XingFang
Department département
Laboratory Medicine and Pathology
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
519
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Other manufactured products and processes
Area of application fr
Autres produits et procédés de fabrication
Research subject code
3500
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Analytical chemistry
Research subject fr
Chimie analytique
Partie
1
Nb partie
1
Application title
Advanced mass spectrometry applied to UV-treated biopharmaceutical fluids
Keyword
NSERC
Application summary
Trojan Technologies is developing ultraviolet (UV) reactors to disinfect cell-culture media for use inbiopharmaceutical production. These media contain complex mixtures of amino acids, carbohydrates, vitamins,minerals, and, in some cases, serum. The industry has a significant problem with contamination by small,non-enveloped viruses that can evade the conventional filtration and chemical disinfection methods, and UVcan eliminate these infectious agents. The biopharmaceutical industry is adopting sterile, single-use disposabledevices for drug production in order to eliminate the need for on-site cleaning and sterilization, and to increaseproduct safety. Trojan has developed and is testing a prototype disposable UV system based on Teflon, one ofthe few polymers that is UV-transparent.The United States Food and Drug Administration (FDA) requires the evaluation of all wetted parts that maypotentially contaminate the drug supply process to quantify ""leachable and extractible"" compounds. Guidancefor setting limits for leachable and extractible compounds can be found in the United States PharmacopeialConvention (USP) documents (e.g., 661, 1151, 601 and 1664) and the International Conference onHarmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use ICHQ6A. Specific tests and levels are not prescribed, but are determined in consultation with the FDA on acase-by-case basis.The challenge in quantifying leachable compounds from the UV-Teflon devices is that the Teflon present inanalytical instruments such as LC-MS contributes background to the sample being analyzed. Dr Li's team at theUniversity of Alberta has the expertise and specialized equipment to develop methods for addressing thesechallenges. Trojan and Dr. Li's team will solve these issues, creating the potential fro the prototype to enter themarket of disinfecting biopharmaceutical fluids, estimated at tens of millions of dollars annually.